PharmaCyte Biotech, Inc. (PMCB)
PharmaCyte Biotech, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Las Vegas, NV, US. The stock last traded at $0.56, up 1.84% on the session, giving a market capitalisation of $6.0M. On trailing twelve-month figures it carries a trailing P/E of -0.18, a net margin of 0.0%. Its beta of 0.68 implies it has historically moved less than the broad market.
PharmaCyte Biotech, Inc. is a biotechnology firm dedicated to the development and commercialization of advanced cellular therapies within the United States. Their primary therapeutic areas include various forms of cancer, diabetes, and malignant ascites. Central to their efforts is Cell-in-a-Box, their proprietary encapsulation technology which utilizes cellulose to enclose live cells. This innovative platform serves as the foundation for treatments aimed at diverse cancers, such as advanced and inoperable pancreatic cancer, as well as diabetes. The company's pipeline includes therapies for pancreatic and other solid cancerous tumors; a treatment for Type 1 and insulin-dependent Type 2 diabetes involving encapsulated, genetically modified insulin-producing cells; and cancer treatments derived from cannabis plant compounds. To further its research, PharmaCyte maintains collaborative agreements: one with the University of Technology, Sydney, for the creation of melligen cells to combat diabetes, and another with the University of Northern Colorado, focusing on methods for identifying, separating, and quantifying cannabis constituents. Originally established in 1996, the company operated under the name Nuvilex, Inc. before rebranding as PharmaCyte Biotech, Inc. in January 2015. Its corporate headquarters are located in Las Vegas, Nevada.
PharmaCyte Biotech, Inc. is most often compared with the following Healthcare names: